SCHEMBL17216207

SCHEMBL17216207

CCc1ccc([C]=NOCc2ccc(Cl)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.39
▸ AGXT P21549 2/20 0.39
▸ CYP2A6 P11509 1/20 0.39
▸ L3MBTL1 Q9Y468 5/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ AGTR1 P30556 1/20 0.37
▸ MAOB P27338 6/20 0.37
▸ APP P05067 1/20 0.37
▸ MAOA P21397 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.34
▸ GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17217407 1.00 IDO1 (0.39) IDO1AGXTCYP2A6L3MBTL1MEN1
SCHEMBL17217404 1.00 IDO1 (0.39) IDO1AGXTCYP2A6L3MBTL1MEN1
SCHEMBL17216205 1.00 IDO1 (0.39) IDO1AGXTCYP2A6L3MBTL1MEN1
SCHEMBL17219096 0.92 IDO1 (0.45) IDO1AGXTL3MBTL1MEN1KMT2A
SCHEMBL17216623 0.92 CYP2A6 (0.45) CYP2A6L3MBTL1KMT2AMAPTTDP1
SCHEMBL17216620 0.92 CYP2A6 (0.45) CYP2A6L3MBTL1KMT2AMAPTTDP1
SCHEMBL17219095 0.92 IDO1 (0.45) IDO1AGXTL3MBTL1MEN1KMT2A
SCHEMBL17215944 0.87 RAB9A (0.42) IDO1AGXTL3MBTL1MEN1KMT2A
SCHEMBL17215941 0.87 RAB9A (0.42) IDO1AGXTL3MBTL1MEN1KMT2A
SCHEMBL17218235 0.87 RAB9A (0.42) IDO1AGXTL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 IDO1 2882/4885AGXT 1423/4885CYP2A6 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback